Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation.
Journal: NPJ vaccines
Published: December 29, 2025
The potential public health benefit of live-attenuated pertussis vaccines.
Journal: Expert opinion on drug delivery
Published: November 14, 2025
Intranasal sensitization model of alopecia areata using pertussis toxin as adjuvant.
Journal: Frontiers in immunology
Published: July 23, 2024
Neonatal infection with Bordetella pertussis promotes autism-like phenotypes in mice.
Journal: iScience
Published: April 11, 2024
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
Journal: Lancet (London, England)
Published: July 28, 2022
Manufacture of a Stable Lyophilized Formulation of the Live Attenuated Pertussis Vaccine BPZE1.
Journal: Vaccines
Published: August 18, 2020
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
Journal: The Lancet. Infectious diseases
Published: January 08, 2020
Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.
Journal: The Journal of clinical investigation
Published: November 14, 2019
The Potential Role of Subclinical Bordetella pertussis Infection in Epilepsy.
Journal: Frontiers in cellular and infection microbiology
Published: April 06, 2019
Last Updated: 09/26/2026